Rahul Rao is a Senior Research Analyst at a prominent financial institution. He specializes in finance, trading, and energy sectors, with a keen focus on energy policy, sustainability, and renewable energy. His insights and expertise have been featured in notable publications such as Inverse, Popular Science, and Scientific American.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Rahul Rao's coverage suggests a deep interest in scientific developments, specifically within space exploration, astronomy, nuclear fusion, and science and technology. His articles often include data citations and expert commentary.
Given the scientific focus of his work, Rahul would likely be receptive to pitches that offer insights from credible experts within these fields. Pitches offering access to new research findings or exclusive interviews with leading scientists involved in cutting-edge projects related to space exploration or nuclear fusion could capture his attention.
As there is no specific geographic focus mentioned for Rahul's coverage, it appears he takes an international view on scientific advancements without being limited by location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Rahul Rao
Following the exit of the Piramal family, Renuka Ramnath's Multiples PE has taken operational control of VIP Industries. Despite a massive market share collapse to 29% and a negative EBITDA margin shock in FY26, a rigid inventory clean-up, debt reduction, and a comprehensive leadership overhaul suggest a classic private equity turnaround play is underway for the iconic Indian luggage brand.
By: Rahul Rao
Acutaas Chemicals was once viewed primarily as a pharmaceutical intermediates manufacturer. Today, the company is building a broader specialty chemicals platform spanning CDMO, battery electrolyte additives, semiconductor chemicals, and fine chemistry. As multiple growth engines begin scaling simultaneously, the key question is whether execution can justify the sharp valuation re-rating already underway.
Manorama Industries' FY26 revenue grew 76%, ROE touched 40%, and EBITDA margin expanded to 27%. The stock now trades at 34x earnings. But after two years of negative operating cash flow before a sharp rebound in FY26, the key question is whether margins, capacity expansion, pricing power, and cash conversion can continue to hold together.
Neurodivergent people are AI’s most demanding users. That makes them its most valuable builders, too.
By: Rahul Rao
By shedding ₹1,000 crore in gross block and eliminating ₹50 crore in annual depreciation, the company transforms into India’s only listed asset-light renewable O&M pure-play, significantly lowering forward valuation multiples for FY27.
By: Rahul Rao
As India races to build capacity for peptide-based drugs, one company sits quietly upstream of the manufacturing chain. Alkyl Amines Chemicals manufactures critical reagents used in peptide synthesis and pharmaceutical chemistry. With global leadership in several amine molecules and exposure to the GLP-1 ecosystem, the company is emerging as a key beneficiary of India's pharmaceutical manufacturing scale-up. The question now is whether execution can keep pace with the scale of the opportunity.
By: Rahul Rao
A 2W-metal company is quietly buying its way into aerospace and satellite supply chains. It saw its FY26 profit after tax jump 41%, reduced its net debt to near zero, and watched its stock double. At ~40x, is the aerospace bet already in the price?
By: Rahul Rao
This firm has approved a vertical demerger scheme to spin off its financial services arm, paving the way for its Crown Jewel, Care Health Insurance, to be re-rated independently once strict regulatory promoter thresholds are met.
By: Rahul Rao
A small-cap API intermediate manufacturer is attempting a transformation into a global pharmaceutical platform through Rs 3,000 crore of acquisitions, including Sanofi's anti-TB brands and Japan's MicroBiopharm. The opportunity is compelling, but can the balance sheet support the ambition?
By: Rahul Rao
Over the last few years, Supriya Life Sciences has expanded beyond its traditional API business. By targeting markets dominated by Chinese suppliers and investing in formulations, contrast media APIs, peptides, and CDMO services, the company is increasing its presence across the pharmaceutical value chain. The key question is whether these initiatives can transform it into a diversified pharmaceutical player.
